Glyclopyramide
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
4-chloro-N-[(pyrrolidin-1-ylamino)carbonyl]benzenesulfonamide
|
|
| Clinical data | |
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 631-27-6  |
| ATC code | None |
| PubChem | CID: 71793 |
| ChemSpider | 64820 |
| UNII | KE474IKG1W  |
| KEGG | D01799 |
| Chemical data | |
| Formula | C11H14ClN3O3S |
| Molecular mass | 303.76 g/mol |
|
|
|
|
 (what is this?) (verify) |
Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.
It is classified as second generation.[1]
References[edit]
- ^ Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese) 38 (1): 11–27. PMID 14570054.
- (Japanese) Deamelin-S 250 mg Tablets
|
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
